Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
- Status
- COMPLETED
- Phase
- PHASE1
Daratumumab for the Treatment of Patients With AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1
"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
- Status
- COMPLETED
- Phase
- PHASE2